E Scape Bio

About E Scape Bio

E Scape Bio, founded in 2015, is a clinical-stage biopharmaceutical company that operated from South San Francisco, California, focusing on developing small-molecule therapeutics for genetically defined neurodegenerative diseases. The company was co-founded by scientists Robert Mahley, M.D., Ph.D., and Yadong Huang, M.D., Ph.D., from the Gladstone Institutes. Their extensive research on the role of Apolipoprotein E (ApoE) in the nervous system, particularly linking the ApoE4 variant to Alzheimer's disease, formed the scientific bedrock of the company.

The company's business model was centered on precision medicine, aiming to create disease-modifying treatments for specific patient subpopulations where a genetic alteration is a known driver of the disease. This strategy was intended to increase the probability of success by targeting homogenous patient groups with clear biological markers. E Scape Bio's revenue model was based on the successful development and subsequent commercialization or partnership of its therapeutic candidates. The company successfully raised a total of $167 million over three funding rounds to finance its research and development operations. A significant Series A round in 2017 raised $63 million, and a later Series C crossover financing in 2020 secured an additional $73 million from a syndicate of investors including Wellington Management, OrbiMed, and Johnson & Johnson Innovation.

The product pipeline included several promising candidates. The initial lead program targeted the ApoE4 protein structure, a significant genetic risk factor for late-onset Alzheimer's disease. Over time, the pipeline expanded to address other conditions. This included ESB1609, a novel, orally administered S1P5 receptor agonist designed to be brain-penetrant for treating CNS-related lysosomal storage disorders. This program was acquired from AbbVie in 2018, positioning the company to advance towards clinical trials. Another key asset was a mutant-selective LRRK2 G2019S kinase inhibitor for Parkinson's Disease patients who carry that specific genetic variant. By September 2020, ESB1609 was in a Phase 1 multiple ascending dose study in healthy volunteers, while the LRRK2 inhibitor was in IND-enabling studies. However, by mid-2025, the company was reported to be inactive or deadpooled.

In August 2018, biopharma veteran Julie Anne Smith was appointed President and CEO, bringing extensive experience in leading companies through the development and commercialization of therapies for neurodegenerative and orphan diseases. Her background includes leadership roles at Nuredis and Raptor Pharmaceuticals. She succeeded interim CEO Dr. Leon Chen of OrbiMed Advisors to guide the company as it neared clinical development.